NCT05621590

MLC901 in Hypoxic-ischemic Brain Injury Patients; A Double-blind, Randomized Placebo-controlled Trial

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: Shahid Beheshti University of Medical Sciences · Academic / Other
• Sex: All
• Age: 14 Years
• Healthy volunteers: Not accepted

Summary

In a randomized, placebo-controlled trial, 35 patients with HIBI were randomly designated to receive either MLC901 or placebo capsules over six months. We evaluated patients in two groups by modified Rankin Scale (mRS) and Glasgow outcome scale (GOS) to examine their state of disability and recovery

Conditions

• Hypoxic Ischaemic Encephalopathy Due to Cardiac Arrest

Interventions

Type	Name	Description
DRUG	MLC 901	MLC901, also known as NeuroAiDII, is a capsule form of drug which should be taken orally and combines nine herbal components
DRUG	Placebo	placebo capsules filled with stevia sweetened powder

Timeline

• Start date: 2020-03-10
• Primary completion: 2022-08-12
• Completion: 2022-08-12
• First posted: 2022-11-18
• Last updated: 2022-11-18

Locations

1 site across 1 country: Iran